Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

LESSONS LEARNED: Advanced germ cell tumors are aggressive and associated with poor prognosis. Pembrolizumab was overall well tolerated in 12 heavily pretreated patients. Three patients had radiographic stable disease that lasted for 10.9 months, 5.5 months, and 4.5 months, respectively. Published da...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Tsimberidou, Apostolia‐Maria, Vo, Henry Hiep, Subbiah, Vivek, Janku, Filip, Piha‐Paul, Sarina, Yilmaz, Bulent, Gong, Jing, Naqvi, Mohammad Faraz, Tu, Shi‐Ming, Campbell, Matthew, Meric‐Bernstam, Funda, Naing, Aung
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2021
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265349/
https://ncbi.nlm.nih.gov/pubmed/33491277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13682
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky